Skip to main content
SpringerLink
Log in

Viral Load — Bedeutung für die individualisierte Therapie

Viral load — Its importance for an individual treatment

  • Übersicht
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

Zusammenfassung

Die Behandlung der HIV-Erkrankung hat sich durch ein neues pathophysiologisches Verständnis grundlegend gewandelt. Der leitende Laborparameter für die Therapieentscheidungen ist heute die Bestimmung der im Plasma gemessenen Viruslast.

Elf Medikamente stehen in Deutschland zur Reduktion der HIV-Menge im Blut zur Verfügung. Etwa zwei Drittel der Behandler beginnen mit einer Zweifachkombination. Protease-Inhibitoren stellen eine wichtige Erweiterung der Therapieoptionen dar.

Summary

The treatment of HIV infection/AIDS has changed dramatically because of a new pathophysiological understanding of this disease. The most important laboratory parameter for the management of antiretroviral therapy is the direct measurement of virus load in plasma.

In Germany 11 different medications are available to the patient for reduction of his viral load in blood and possibly tissue, i.e. lymph-nodes. The majority (about 2/3) of physicians begin to treat with double combination therapy. Protease inhibitors are an important addition to the therapeutic arsenal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bush, C. E., R. M. Donovan, N. Markowitz, D. Baxa, P. Kvale, L. D. Saravolatz: Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. J. clin. Microbiol. 34 (1996), 970–972.

    PubMed  CAS  Google Scholar 

  2. Cao, Y., L. Qin, L. Zhang, J. Safrit, D. D. Ho: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New Engl. J. Med. 201 (1995), 202–208.

    Google Scholar 

  3. Cheeseman.

  4. Delta-Studie: Durchbruch für Kombinationstherapie bei HIV-Infektion. Info IV/95 des RKI 1995.

  5. Dewar, R. L., H. C. Highbarger, M. D. Sarmiento, J. A. Todd, M. B. Vasudevachari, T. Davey, A. Kovacs, N. P. Salzman, C. H. Lane, M. S. Urdea: Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. infect. Dis. 170 (1994), 172–179.

    Google Scholar 

  6. Dickover, R. E., E. M. Garratty, St. A. Herman, M. S. Sim, S. Plaeger, P. J. Bover, M. Keller, A. Deveikis, E. R. Stiehm, Y. J. Bryson: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. J. Amer. med. Ass. 275 (1996), 599–605.

    Article  CAS  Google Scholar 

  7. Emini, E. A.: Protease inhibitors. 3rd Conference on Retroviruses and Opportunistic Infections. Washington D.C. January 28th. 1996.

  8. Eron, J. J., S. L. Benoit, J. Jemsek: Treatment with Lamivudine, Zidovudine or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New Engl. J. Med. 21 (1995).

  9. Fang, G., H. Burger, P. Tropper, S. Nachman, H. Viscosi, R. Moore, R. Grimson, G. Baxter, N. Sporysz, C. Reyelt, N. Hutcheon, B. Weiser: QC-PCR quantitation of HIV 1 plasma RNA level during pregnancy: relationship to mother-to-child transmission and antiviral therapy. 2nd National Conference Human Retroviruses and Related Infections. Washington D. C. 1995, Abstract No. 441.

  10. Havlier, D., M. M. McLaughlin, D. D. Richman: A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus infected patients with CD4 cell count of >500/mm E3; AIDS clinical trials group control 20 B. J. infect. Dis. 172 (1995), 1379–1383.

    Google Scholar 

  11. Ho, D. D., A. U. Neuman, A. S. Perelson, W. Chen, J. M. Leonard, M. Markowitz: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (Lond.) 373 (1995), 123–126.

    Article  CAS  Google Scholar 

  12. Katlama, C., J. M. Molina, W. Rozenbaum: Stavudine (D4T) in HIV-infected patients with CD4>350/mm3: results of a double-blind randomised placebo controlled study. 3rd Conference on Retroviruses and Opportunistic Infections, Washington D. C. 1996.

  13. Jäger, H., R. Wagner: Zuverlässig und schnell per Virusquantifizierung. Sonderdruck. Dtsch. Ärztebl. 50/A (1995), 3545–3548.

    Google Scholar 

  14. Mellors, J. W., L. A. Kingsley, C. R. Rinaldo, J. A. Todd, B. S. Hoo, R. P. Kokka, P. Gupta: Quantitation of HIV-1 RNA in plasma predicts outcome of HIV-1 after seroconversion. Ann. intern. Med. 122 (1995), 573–579.

    PubMed  CAS  Google Scholar 

  15. Molla, A.: The potential of ritonavir in combination therapy. Workshop: HIV protease inhibitors. San Francisco June 11th, 1996.

  16. Para, M. F., M. Fisch, P. Meehan, W. Freimuth, G. Morse, L. Demeter, K. Wood, R. Shafer, J. Holden-Wiltse: ACTG-260: Randomized phase I/II dose-ranging trial of the anti-activity of delavirdine. Abstract 1996.

  17. Piatak, M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, J. D. Lifson: High levels of HIV-1 plasma RNA during all stages of infection determined by competitive PCR. Science 259 (1993), 1749–1754.

    Article  PubMed  CAS  Google Scholar 

  18. Pollard, R., D. Peterson, D. Hardy: Antiviral effect and safety of stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects in an ongoing pilot randomized double blinded trial. 3rd Conference on Retroviruses and Opportunistic Infections, Washington D. c. 1996.

  19. Ruffault, A., C. Michelet, C. Jacquelinet, O. Guist’hau, N. Genetet, C. Bariou, R. Colimon, F. Cartier: The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year-follow-up-study. J. Aids human Retrovir. 9 (1995), 243–248.

    CAS  Google Scholar 

  20. Shepp, D. H., A. Ashra: Effect of didanosine on human immunodeficiency virus viremia and antigenemia in patients with advanced disease: correlation with clinical response. J. infect. Dis. 167 (1993), 30–35.

    PubMed  CAS  Google Scholar 

  21. Tiller, F. W., E. Wolf, F. Gräbnitz, E. Jägel-Guedes, H. Jäger: Application of Q-NASBA for determining HIV-1 viral load in human plasma. Clin. Lab. 41 (1995), 769–772.

    Google Scholar 

  22. Volberding, P. A.: HIV quantification — clinical applications. Lancet 347 (1996), 71–73.

    Article  PubMed  CAS  Google Scholar 

  23. Wie, X., S. K. Gosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoefer, M. A. Novak, B. H. Hahn, M. S. Saag, G. M. Shaw: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (Lond.) 373 (1995), 117–122.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. KIS-Kuratorium für Immunschwäche, Mozartstraße 3, D-80336, München

    Hans Jäger

Authors
  1. Hans Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jäger, H. Viral Load — Bedeutung für die individualisierte Therapie. Med Klin 92, 344–346 (1997). https://doi.org/10.1007/BF03044775

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03044775

Search

Navigation